SCHEDULE: RA Capital Exits Alector Stake, Reports Zero Ownership

RA Capital Management and its affiliates have filed an amended Schedule 13G, indicating they no longer hold beneficial ownership in Alector, Inc.

Summary

• RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (collectively, the "Reporting Persons") have filed an Amendment No. 1 to Schedule 13G.
• As of June 30, 2025, the Reporting Persons collectively beneficially own 0.00 shares of Alector, Inc. common stock.
• This represents 0.0% of the class of Alector, Inc. common stock.
• The filing indicates that the Reporting Persons hold no sole or shared voting power, nor sole or shared dispositive power over Alector's shares.
• The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13G.

Sentiment

Score: 3

Explanation: The filing indicates a complete divestment by a significant institutional investor, which is generally perceived as a negative signal by the market, suggesting a lack of conviction or a strategic portfolio reallocation.

Negatives

• A significant institutional investor, RA Capital Management and its affiliates, has fully divested its beneficial ownership in Alector, Inc., reducing its stake to 0%.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding Alector, Inc.'s future performance or strategic direction.

Management Comments

• The Reporting Persons certify that, to the best of their knowledge and belief, the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer, and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 14a-11.

Industry Context

RA Capital Management is a prominent investment firm specializing in the healthcare and life sciences sectors. Their complete divestment from Alector, Inc., a biotechnology company, could be interpreted by the market as a shift in their investment thesis or a re-evaluation of Alector's prospects within the competitive biotech landscape.

Stakeholder Impact

• Shareholders may view the complete divestment by a notable institutional investor negatively, potentially leading to decreased investor confidence and downward pressure on the stock price.

Key Dates

Recommendation

The complete divestment by RA Capital Management, a notable healthcare investor, suggests a lack of conviction or a strategic portfolio reallocation. While the filing provides no reasons for the exit, such a significant move by an institutional holder could signal potential concerns or a shift in investment thesis, warranting caution for current and prospective investors. A 'hold' recommendation is prudent to observe market reaction and any further company developments.

Keywords

Alector, ALXO, RA Capital Management, Schedule 13G, Beneficial Ownership, Institutional Investor, Biotech, Healthcare Investment, Divestment